With every day passing, and the headlines getting further hogged by worrisome developments regarding the spread of the coronavirus, the need for a treatment or vaccine becomes more acute.The market has recognized the need, too. While the bloodbath across all the major indexes continues, apart from a few outliers, the biotech companies searching for solutions are among the only names to have experienced any upward movement recently. Which brings us to small-cap biotech firm CytoDyn Inc. (CYDY).Yesterday, CytoDyn reported it had filed an Investigational New Drug (IND) application to launch a Phase 2 trial in the U.S. with leronlimab (PRO 140) in patients infected with the COVID-19 coronavirus.CytoDyn’s management have noted that deaths caused by COVID-19 are mostly a result of acute respiratory distress syndrome (ARDS), as the virus in human lungs causes an influx of macrophage and immune cells and the cytokines released result in even more influx of immune...
Contracts on the S&P 500, Dow and Nasdaq kicked off the overnight session lower, suggesting the equity market carnage from Monday was set to continue....